Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

LySeqST: a targeted sequencing assay for robust genomic classification of diffuse large B-cell lymphoma.

Blood advances·2026
Same author

Diagnosis-to-treatment interval is associated with outcomes in follicular lymphoma treated with immunochemotherapy.

Blood·2026
Same author

Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.

Blood·2026
Same author

Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis.

American journal of hematology·2026
Same author

Bleomycin omission in limited-stage classic Hodgkin lymphoma with negative PET scan after two cycles of ABVD.

Haematologica·2026
Same author

Immunogenicity and safety of a third and subsequent COVID-19 vaccine doses in patients with plasma cell dyscrasias.

Blood advances·2026

Related Experiment Video

Updated: May 18, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Chemotherapy alone for localized diffuse large B-cell lymphoma.

Laurie H Sehn1

  • 1Centre for Lymphoid Cancer, British Columbia Cancer Agency and the University of British Columbia, Vancouver, Canada. lsehn@bccancer.bc.ca

Cancer Journal (Sudbury, Mass.)
|September 26, 2012
PubMed
Summary

For diffuse large B-cell lymphoma (DLBCL), involved-field radiation therapy (IFRT) may no longer be standard for limited-stage disease. Tailored treatment based on individual patient factors and response is becoming the preferred approach.

Related Experiment Videos

Last Updated: May 18, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Area of Science:

  • Oncology
  • Hematology
  • Radiation Oncology

Background:

  • Diffuse large B-cell lymphoma (DLBCL) is diagnosed with limited-stage disease in 25-30% of patients.
  • Treatment historically involved systemic therapy plus involved-field radiation therapy (IFRT).
  • IFRT improves local control but not necessarily long-term outcomes, and carries toxicity risks.

Purpose of the Study:

  • To evaluate the continued justification for routine IFRT in limited-stage DLBCL.
  • To advocate for a shift towards tailored treatment strategies.

Main Methods:

  • Review of current treatment paradigms for limited-stage DLBCL.
  • Analysis of the benefits and risks of IFRT in the context of modern systemic therapies.
  • Consideration of factors for personalized treatment approaches.

Main Results:

  • The routine use of IFRT in all limited-stage DLBCL patients is increasingly questionable.
  • Improved systemic therapies diminish the necessity of IFRT for all cases.
  • Tailored therapy, considering patient status and disease characteristics, is proposed.

Conclusions:

  • The role of IFRT in limited-stage DLBCL requires re-evaluation.
  • Personalized treatment strategies, guided by individual patient factors and early response, are recommended.
  • Future approaches will likely prioritize biologic insights for DLBCL treatment.